Article
SLC1A1-mediated cellular and mitochondrial influx of R-2-hydroxyglutarate in vascular endothelial cells promotes tumor angiogenesis in IDH1-mutant solid tumors.
Cell research - 1 Jul 2022
Wang Xiaomin, Chen Ziqi, Xu Jun, Tang Shuai, An Nan, Jiang Lei, Zhang Yixiang, Zhang Shaoying, Zhang Qingli, Shen Yanyan, Chen Shijie, Lan Xiaojing, Wang Ting, Zhai Linhui, Cao Siyuwei, Guo Siqi, Liu Yingluo, Bi Aiwei, Chen Yuehong, Gai Xiameng, Duan Yichen, Zheng Ying, Fu Yixian, Li Yize, Yuan Liang, Tong Linjiang, Mo Kun, Wang Mingcheng, Lin Shu-Hai, Tan Minjia, Luo Cheng, Chen Yi, Liu Jia, Zhang Qiansen, Li Leping, Huang Min
Abstract excerpt
Mutant isocitrate dehydrogenase 1 (mIDH1) drives tumorigenesis via producing oncometabolite R-2-hydroxyglutarate (R-2-HG) across various tumor types. However, mIDH1 inhibitors appear only effective in hematological tumors. The therapeutic benefit in solid tumors remains elusive, likely due to the complex tumor microenvironment. In this study, we discover that R-2-HG produced by IDH1-mutant tumor cells is...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.